Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

An ideal case example of this working would be for the available generics and biosimilars that we have in the multiple sclerosis therapeutic area; these medications often have lower list prices than ...

Confirmed six-month disability progression rates over 4 years were similar in patients given the oral statin or a placebo in ...

Results of a world-first phase 3 trial for secondary progressive multiple sclerosis (MS), led by UCL researchers, have shown ...

A new study reveals how gender disparities cause therapeutic inertia in MS treatment for women, highlighting delays and ...

Key biomarkers identified can now predict disability progression in multiple sclerosis, offering potential for more ...

Dr. Barot joins an already accomplished team of medical experts at ADIA Nutrition, bringing with him a wealth of knowledge ...

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS POST ECTRIMS 2024 Paris, 23 September 2024, 5.45pm CET AB Science SA (Euronext - ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting ...

Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end ...

B.Riley Financial analyst William Wood has reiterated their bullish stance on IMUX stock, giving a Buy rating on September 16. William Wood ...